• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjclinpharmLink to Publisher's site
Br J Clin Pharmacol. May 2010; 69(5): 543–552.
PMCID: PMC2856056

Potentially inappropriate prescribing and cost outcomes for older people: a national population study



Optimization of drug prescribing in older populations is a priority due to the significant clinical and economic costs of drug-related illness. This study aimed to: (i) estimate the prevalence of potentially inappropriate prescribing (PIP) in a national Irish older population using European specific explicit prescribing criteria; (ii) investigate the association between PIP, number of drug classes, gender and age and; (iii) establish the total cost of PIP.


This was a retrospective national population study (n= 338 801) using the Health Service Executive Primary Care Reimbursement Service (HSE-PCRS) pharmacy claims database. The HSE-PCRS uses the WHO Anatomical Therapeutic Chemical (ATC) classification system and details of every drug dispensed and claimants' demographic data are available. Thirty PIP indicators (STOPP) were applied to prescription claims for those ≥70 years in Ireland in 2007. STOPP is a physiological system based screening tool of older persons' potentially inappropriate prescriptions assessing drug–drug and drug–disease interactions, dose and duration.


In our study population PIP prevalence was 36% (121 454 claimants). The main contributors to this were: 56 560 (17%) prescribed proton pump inhibitors at maximum therapeutic dose for >8 weeks, 29 691 (9%) prescribed non-steroidal anti-inflammatories for >3 months, 17 676 (5%) prescribed long-acting benzodiazepines for >1 month and 16 201 (5%) prescribed duplicate drugs. The main determinant of PIP was polypharmacy. The likelihood of PIP increased with a significant linear and quadratic trend (P < 0.0001) with the number of drug classes.The maximum net ingredient cost of PIP was estimated to be €38 664 640. Total PIP expenditure was estimated to be €45 631 319, 9% of the overall expenditure on pharmaceuticals in those ≥70 years in 2007.


The findings identify a high prevalence of PIP in Ireland with significant cost consequences.

Keywords: elderly, inappropriate prescribing, medication cost, population based, Screening Tool of Older Peoples Prescriptions (STOPP)


  • Potentially inappropriate prescribing (PIP) refers to medications that should generally be avoided in older populations and doses or frequencies of administrations that should not be exceeded. Studies of PIP have been primarily based on US indicators of appropriateness such as the Beers criteria due to the lack of European specific indicators.
  • PIP has not been assessed in full national samples.
  • The total cost of PIP drugs and the cost in relation to overall national pharmaceutical expenditure have not been described.


  • One third of the Irish population aged ≥70 years were prescribed at least one potentially inappropriate medication in 2007 based on European criteria.
  • There was a signficant association between polypharmacy and the risk of PIP. Polypharmacy was evaluated as the number of different repeat drug classes (≥ three prescription claims) per claimant.
  • The most prevalent PIP drugs were: proton pump inhibitors at maximum therapeutic dosage for >8 weeks (40 mg daily omeprazole, pantoprazole and esomeprazole, 30 mg daily lansoprazole and 20 mg daily rabeprazole); non-steroidal anti-inflammatories for >3 months; long-acting benzodiazepines for >1 month and drug duplication within the same therapeutic class.
  • The total expenditure on potentially inappropriate drugs was €45 631 319 in 2007 which is 9% of the overall expenditure on pharmaceuticals in those aged ≥70 years in Ireland.


Optimization of drug prescribing in older populations is a priority due to the significant clinical and economic costs of drug related illness. Inappropriate prescribing in older people is associated with increases in morbidity, adverse drug events, hospitalization and mortality [1, 2]. However the selection of appropriate medication in older people is a challenging and complex process. Older people are particularly vulnerable to inappropriate prescribing because of their multiple drug regimens, co-morbid conditions and age associated physiological changes which can alter their pharmacokinetics and enhance their pharmacodynamic sensitivity to specific drugs [3]. In general, medicines in older people are considered appropriate when they have a clear evidence-based indication, are well tolerated in the majority and are cost-effective. In contrast, medicines that are potentially inappropriate have no clear evidence-based indication, carry a substantially higher risk of adverse side-effects compared with use in younger people or are not cost effective [4].

Appropriateness of prescribing in older people can be assessed by process (i.e. what providers do) or outcome measures (i.e. patient outcomes) which are implicit or explicit [3]. Implicit process measures are based on a clinician's judgment of appropriateness for the individual patient [5]. Explicit process measures are criterion based and are developed from published reviews, expert opinion and/or consensus techniques and should be generalizable across countries [6]. These measures consist of drugs to be avoided in older people, independent of diagnoses or in the context of certain diagnoses [79].

The US Beers criteria are the most frequently used and validated explicit process measure [10, 11]. However in the context of European prescribing Beers criteria have several limitations. Some of the limitations include the fact that almost half of the drugs that make up the criteria are unavailable for prescribers [12, 13], several of the drugs are not contra-indicated in older people as per the British National Formulary (BNF), e.g. doxazosin [4], whereas other contra-indicated drugs are omitted [13]. The Beers criteria do not consider drug–drug interactions, duration of treatment, varying indications for certain drugs, e.g. low-dose amitriptyline and neuropathic pain (BNF) and underuse of indicated drugs [3, 4]. Given the limitations of the Beers criteria, a more comprehensive explicit process measure of potentially inappropriate prescribing (PIP) has recently been developed and validated for use in European countries, the Screening Tool of Older Peoples Prescriptions (STOPP) [14].

There have been few studies of PIP in the general population of older people [12, 15, 16]. Previous research is limited by having focused on specific groups in particular settings such as geriatric units, nursing homes and hospitals as well as having measured PIP using Beers criteria. There is also a limited understanding of the risk factors associated with PIP and results from previous studies have been inconclusive [11, 15, 17]. The overall aim of this study was to estimate the prevalence of PIP in the national Irish population aged ≥70 years, in 2007 using thirty STOPP criteria. Additional objectives included: (i) estimation of the prevalence of PIP per individual STOPP criteria by physiological system; (ii) investigation of the association between PIP, number of drug classes, gender and age and; (iii) establishing the total cost of PIP drugs and the cost in relation to overall national pharmaceutical expenditure.


Study population

The National Shared Services Primary Care Reimbursement Service of the Health Service Executive in Ireland (HSE-PCRS) pharmacy claims database of dispensed medications was used to identify the study population. The HSE-PCRS general medical card scheme provides free health services including medications to eligible persons in Ireland. The HSE-PCRS scheme is means tested for those less than 70 years of age, and free to all those ≥70 years between July 2001 and December 2008. It is estimated that over 97% of this age group nationally avail of the scheme [18].

The HSE-PCRS pharmacy claims database provides details on monthly dispensed medications for each individual within the scheme. Prescriptions are coded using the World Health Organisation Anatomical Therapeutic Chemical (ATC) classification system [19] and prescriber information, defined daily doses (DDD), strength, quantity, method and unit of administration of each drug dispensed, ingredient costs and pharmacist dispensing fees per item dispensed are available. Gender, age group and health board region of each claimant is also recorded, but no diagnosis or outcomes are reported.

Explicit measurement of potentially inappropriate prescribing

STOPP is a physiological system based screening tool and comprises sixty-five clinically significant criteria which take drug–drug and drug–disease interactions, drug doses and duration into consideration [14]. STOPP considers cost-effectiveness as well as clinical effectiveness and includes the removal of any potentially unnecessary drugs. STOPP was validated using the Delphi consensus technique by an eighteen member expert panel in geriatric pharmacotherapy from the UK and Ireland. Inter-rater reliability is high [14, 20].

Thirty STOPP criteria were applied to prescription claims data for all those aged 70 years and older in Ireland in 2007 (supplemental Table S1). The thirty criteria were considered applicable to pharmacy claims data without diagnosis information on a consensus basis by an expert panel of five members in geriatric pharmacotherapy, clinical pharmacology, pharmacoepidemiology and academic general practice. Prescription drugs for the treatment of certain disease conditions were identified and used as proxies for diagnosis where possible, e.g. dementia (ATC, N06D), Parkinson's disease (ATC, N04), epilepsy (ATC, N03, excluding gabapentin and pregabalin as also prescribed for neuropathic pain, BNF 4.7.3), chronic obstructive pulmonary disease (COPD) (ATC, R03BA, R03BB, R03CC02, R03CC03, R03DA04), glaucoma (ATC, S01ED), type 2 diabetes (ATC, A10B), gout (ATC, M04AA01) [18, 21]. Duplicate classes of medicine (on the same prescription claim) were assessed for five medications – opiates, non-steroidal anti-inflammatory drugs (NSAIDs), selective serotonin re-uptake inhibitors (SSRIs), loop diuretics and angiotensin converting enzyme inhibitors (ACE inhibitors).

Criteria which specified a particular duration were assessed by consecutive months of prescription refills for the period commencing January 2007 to December 2007 (lead-in period October to December 2006 included) e.g. long-acting benzodiazepines >1 month, NSAIDs >3 months. Criteria which specified a particular dosage that should not be exceeded e.g. proton pump inhibitors (PPIs) at maximum therapeutic dosage for >8 weeks (40 mg daily omeprazole, pantoprazole and esomeprazole, 30 mg daily lansoprazole and 20 mg daily rabeprazole) were evaluated by calculating the prescribed daily dose for each claimant according to details on the DDD, strength, quantity, administration, unit of measurement and packsize of the dispensed medication for the specified time period. The duration and dosage of PPI prescribing was assessed for a 1 year continuous period for each claimant e.g. January 2007 to January 2008 (baseline period 8 weeks at maximum therapeutic dosage). PPI dosage was classified as maximum or maintenance dosage at the end of each month according to the calculated prescribed monthly dose.

Claimants were categorized by gender and age group (70–74 years) and (≥75 years). The total number of prescriptions for each different drug class (the first three characters of the ATC code) was calculated for each claimant over the year; each claimant was required to receive at least three prescriptions per different drug class to be included as a measure of a repeat drug class. Polypharmacy was evaluated as the number of different repeat drug classes per claimant ranging from zero (reference group) to ten or more drug classes [15, 22, 23]. Costs were calculated as the net ingredient cost (NIC) of the dispensed drug and the total expenditure which included NIC, value added tax and pharmacist dispensing fee. Costs were adjusted for claimants receiving the same medication for more than one criteria. Costs also excluded the duration of prescribing that was deemed appropriate, e.g. 1 month for long-acting benzodiazepines, 3 months for NSAIDs.

Data analysis

The overall prevalence of PIP and the prevalence per individual STOPP criteria in 2007 were calculated as a proportion of all eligible persons ≥70 years. The association between any (vs. no) PIP and polypharmacy (categorized as 0 vs. 1, 2, …… 10+ repeat drug classes), age and gender was assessed using logistic regression presenting adjusted odds ratios (OR) and 95% confidence intervals. Finally, the maximum NIC and total expenditure for all potentially inappropriate medications in 2007 were calculated. Data analysis was performed using SAS statistical software package version 9.1 (SAS Institute Inc. Cary, NC, USA). Statistical significance at P < 0.05 was assumed.


Population descriptive statistics

In 2007, a total of 338 801 people ≥70 years in Ireland were identified from the HSE-PCRS pharmacy database of which 194 460 (57%) were female and 210 515 (62%) were aged ≥75 years.

Overall prevalence of PIP in 2007

The overall prevalence of PIP in 2007 considering all thirty STOPP criteria was 36% (121 454). A quarter of the population, 83 959 individuals, were prescribed one potentially inappropriate medication, 27 392 (8%) were prescribed two and 10 103 (3%) were prescribed three or more.

Prevalence of PIP according to individual STOPP criteria in 2007

Table 1 presents the prevalence of each of the individual STOPP criteria by physiological system. PPIs at maximum therapeutic dosage for >8 weeks was the most frequently prescribed potentially inappropriate drug (56 560, 17%). In this group, 42 151 (75%) continued on PPI therapy for 6 consecutive months with 23 263 (41%) on PPI therapy for a 1 year continuous period. Of those on PPI therapy for a 1 year continuous period, the majority 22 067 (95%) of individuals were prescribed maximum therapeutic dosage (Figure 1).

Table 1
Prevalence of potentially inappropriate prescribing by individual STOPP criteria in 2007
Figure 1
Duration and dosage of PPI therapy for a 1 year continuous period in patients aged ≥70 years on PPI therapy for >8 weeks at maximum therapeutic dosage. 1 year period- January 2007 to January 2008, February 2007 to February 2008. Dosage ...

The second most frequently prescribed potentially inappropriate drugs were NSAIDs for >3 consecutive months, followed by long-acting benzodiazepines and duplicate drugs on the same prescription claim. NSAIDs and opiates were the most frequently prescribed duplication drugs (Table 1). Other STOPP criteria had lower prevalence rates but some were noteworthy as a proportion of the population taking a particular drug for a particular condition, e.g. one-fifth of those with COPD were prescribed β-adrenoceptor blockers.

Factors associated with overall PIP

There was a strong association between PIP and polypharmacy. The likelihood of PIP increased with a significant linear and quadratic trend (P < 0.0001) with the number of different drug classes (Figure 2). PIP was more likely in females vs. males after adjusting for age [odds ratio 1.10, 95% confidence intervals (CI) 1.08, 1.12] and those aged ≥75 years compared with 70–74 years after adjusting for gender (OR 1.28, 95% CI 1.26, 1.30). The strength of the association between PIP and gender and age was reduced after additionally adjusting for polypharmacy (gender (F vs. M), OR 0.91, 95% CI 0.90, 0.93); (age (≥75 years vs. 70–74 years) OR 0.95, 95% CI 0.93, 0.96). No significant collinearity was found between age, gender and polypharmacy.

Figure 2
The association between polypharmacy and PIP in 2007. Repeat prescriptions (minimum of three per year). Odds ratio = odds ratio of any potentially inappropriate drug adjusted for gender and age (reference = 0)

Factors associated with individual STOPP criteria

There was an association between gender and age and the individual STOPP criteria after adjusting for polypharmacy (Table 2). Psychotropic drugs such as tricyclic antidepressants (TCAs) and long-acting benzodiazepines, NSAIDs for >3 months duration and duplicate drug classes on the same prescription claim were more likely to be prescribed in females compared with males. Potentially inappropriate cardiovascular drugs, e.g. aspirin >150 mg day–1 and respiratory drugs were more likely to be prescribed in males compared with females. The prescribing of digoxin >125 µg, TCAs and antimuscarinic drugs with dementia and duplicate loop diuretics was twice as likely in the older age group (≥75 years) compared with the younger age group (70–74 years).

Table 2
The association between gender and age and PIP by individual STOPP criteria in 2007

Cost of potentially inappropriate prescribing in 2007

The total NIC of PIP in 2007 was estimated to be €38 664 640, on average €318 per claimant per year. The total expenditure was estimated to be €45 631 319 which was 9% of the overall expenditure on pharmaceuticals in those aged ≥70 years in Ireland in 2007 [24]. Table 3 presents a breakdown of the NIC and total expenditure on potentially inappropriate medication in 2007 for the highest cost items.

Table 3
The highest NIC and total expenditure (>€500 000) for the individual STOPP criteria as a proportion of the overall NIC and total expenditure of PIP in 2007


Principal findings

This national population based study found that 36% of those ≥70 years received at least one potentially inappropriate medication in 2007 according to the STOPP criteria. The most prevalent PIP drugs were PPIs at maximum therapeutic dosage for >8 weeks, followed by NSAIDs for >3 months and long-acting benzodiazepines for >1 month. The majority of older people prescribed PPIs in 2007 were on PPI therapy for 6 or more consecutive months at maximum therapeutic dosage. Drug duplication on the same prescription claim was also highly prevalent with NSAIDs and opiates as the most frequently prescribed duplication drugs.

Polypharmacy was shown to be strongly associated with PIP. The strength of the overall association between PIP and gender and age was not significant after adjusting for polypharmacy. PIP had a significant impact on the national prescribing budget in 2007 (9% of overall expenditure for those ≥70 years).

Context of PIP in Europe

This study is the first population study to apply the explicit STOPP screening tool for appropriate review of medications in older populations. There have been few studies of PIP in Europe due to the lack of European specific criteria and differences in national drug formularies [13]. Previous population studies in the UK and the Netherlands applied the US Beers criteria and reported lower PIP prevalence rates of 28% and 20%, respectively, with long-acting benzodiazepines and amitriptyline as the most frequently prescribed potentially inappropriate drugs [12, 16].

PPI prescribing for a greater duration and dosage than recommended in the National Institute for Health and Clinical Excellence (NICE) guidelines is not unique to Ireland [25]; 25% to 70% of patients on PPIs have been reported as having no appropriate indication worldwide [26]. PPIs have a high level of efficacy and short-term use is recommended for treating a large range of acid-peptic conditions [25, 26]. Long-term use (≥1 year) in older patients has been associated with accelerated osteoporosis and an increased risk of hip fracture and Clostridium difficle hospital infections [27, 28]. The extent to which older people remain on long-term PPI treatment has significant cost consequences (Table 3).

Long term NSAID use is associated with gastrointestinal adverse effects and hospitalization [29, 30]. Gastroprotective agents are co-prescribed to reduce the risk of adverse effects, if NSAID therapy cannot be stopped [31]. In this study 41% of older patients on PPI therapy of >8 weeks duration were co-prescribed NSAIDs in 2007. NSAID prescribing also had significant cost consequences (Table 3). Long-acting benzodiazepine prevalence rates were higher in Ireland (13%, 5% >1 month) than in population studies from the UK (4%) and the Netherlands (5%) despite the fact that long-acting benzodiazepines have been associated with an increased risk of falls, hip fractures, impaired cognition and dependence problems [12, 16, 32].

PPI therapy withdrawal in older patients requires careful monitoring for disease recurrence but dosage reduction or cessation of treatment is recommended [25, 31]. Long-term users have been shown to cease therapy with no adverse effects to dyspepsia symptom severity and quality of life [33]. Physical therapy and exercise for musculoskeletal complaints may be more appropriate and effective for some older patients than long-term NSAIDs use or simple or compound analgesics [34, 35]. Gastro-protective agents such as PPIs only reduce the risk of adverse effects but do not eliminate the risk. Withdrawal of long-term benzodiazepine use is limited by dependence problems but gradual discontinuation programmes and intervention strategies have been shown to be successful though labour intensive [31, 36, 37]. Indicators for appropriate initiation of benzodiazepine prescribing may provide a more realistic method to reduce potentially inappropriate use [38].

The strong association between polypharmacy and PIP was in accord with previous studies [15, 39]. The prescription of multiple medications in older adults is associated with an increased risk of unnecessary and non-clinically indicated drugs, drug interactions, adherence problems, increased drug costs and adverse drug events; increasing to 58% for five medications [39]. Contrary to this study, previous studies found that women have an increased risk of being prescribed a potentially inappropriate medication compared with men but similarly found no age effect after adjusting for the number of different medications [11, 15, 17]. Polypharmacy and PIP are also associated with the under-prescribing of indicated medicines but this study did not assess this aspect of medication management in older populations [23, 40, 41].

Costs of PIP

There has also been little research on the costs of PIP in relation to overall government pharmaceutical expenditure. STOPP and the newer explicit screening tools for appropriate medication review, consider cost control alongside improving the quality of prescribing [31]. The discontinuation of potentially inappropriate or marginally effective medications can result in significant savings for prescribing budgets; even for potentially inappropriate medications with relatively low prevalence rates, e.g. neuroleptics >1 month (Table 3). Unnecessary duplication of drugs in the same therapeutic class may have adverse effects and increases costs unnecessarily (Table 3); concurrent use of more than one NSAID has been shown to increase the risk of gastrointestinal toxicity [31]. Studies have shown diuretics, warfarin, NSAIDs, SSRIs, β-adrenoceptor blockers and ACE inhibitors to be the drugs most commonly associated with adverse drug events in older populations [29, 30]. Equally the addition of medications to treat an unrecognized adverse reaction – the ‘prescribing cascade’ e.g. anticholingerics for neuroleptic side-effects can also result in additional adverse effects and increases costs.

Strengths and limitations

Our study has a number of possible limitations and it is likely that estimates of PIP are conservative. The lack of detailed diagnosis information in the database limited the applicability of all of the STOPP criteria and the investigation of individual patient factors and differences in drug indication. The STOPP criteria were based on dispensed medications and there may be older people who have not yet been diagnosed with a condition, misdiagnosed or who are not receiving prescribed medication for their diagnosis. The pharmacy claims database is related to prescriptions dispensed and is used to reimburse pharmaceutical costs in Ireland; in general claimants' recorded drug use should reflect actual drug use but it is not known whether patients adhered to their medications. In addition, the database does not include over-the-counter (OTC) items, although this is not likely to be a significant factor as the scheme provides free medical treatment and patients must pay for OTC items.

Notwithstanding the limitations this study has provided Irish population based data on PIP in an older population where limited data have been available [42]. Few national population studies have been undertaken to date and they are important in identifying common PIP issues that may require further investigation, followed by guidelines or incentives to encourage reduction [12, 15, 16]. The application of the STOPP criteria to national population dispensing data rather than prescribing data also provides an opportunity to provide feedback and comparative information on certain key criteria at practice or physician level.

Future research

This study measured an economic outcome, e.g. cost of potentially inappropriate drugs but it did not investigate the association between the STOPP criteria and health outcomes in older populations (e.g. morbidity, mortality). In order to have acceptance in everyday clinical practice explicit process measures of PIP need to be linked to health outcomes. To date there is limited and conflicting evidence [43, 44]. Further research is planned to investigate the association between STOPP and other explicit process measures of PIP and health outcomes, health service utilisation and the overall economic impact of PIP on the health system. Further comparative European population studies are also planned.

Policy implications

Polypharmacy does not imply inappropriate prescribing but it is consistently associated with the risk of PIP (Figure 2) and reducing the number of drugs used by older people through medication review may reduce the risk of PIP, adverse medication outcomes and improve adherence and reduce costs [15, 39]. PIP has been shown to add unnecessary costs to prescribing budgets without providing any additional therapeutic benefits. However while cost control is an important element of a medication review it should not surpass patient safety or access to appropriate medication. Generic prescribing and therapeutic substitution are methods of cost control that do not affect the quality of patient care and offer alternatives when potentially inappropriate medication withdrawal is complex or patients do not concur.

Reduction in PIP requires changes in prescribing behaviour but prescribing guidelines by themselves do not necessarily change behaviour. Computerized screening and clinical decision support tools to implement guidelines by assessing the appropriateness of the medication, the dosage, duration of treatment, drug–disease and drug–drug interactions while balancing the risks of underuse of potentially beneficial drugs are required [3]. While screening tools will never be substitutes for clinical assessment and judgment they can be used to improve prescribing practices and monitor medication use in older populations. Given that life expectancy is increasing worldwide and there will be an associated increase in multi-morbidity, polypharmacy, health service utilisation and drug costs, the development and use of comprehensive, practical and computerized prescribing screening tools for appropriate, safe and effective monitoring of drug prescribing is crucial.

Competing interests

None declared.

Ethical approval: Not required.

We wish to thank the Health Services Executive Primary Care Reimbursement Services (HSE-PCRS) for the use of the prescribing database and the Irish Health Research Board for financial support. We wish to thank Dr Denis O'Mahony, Department of Medicine and Dr Stephen Byrne, School of Pharmacy and University College Cork, Ireland for developing and interpreting the STOPP criteria. We wish in particular to acknowledge Professor John Feely's contribution to this research who died prior to submission of this manuscript.

Supporting information

Additional supporting information may be found in the online version of this article:

Table S1 STOPP criteria applied to HSE-PCRS prescription claims data for all those aged ≥70 years in Ireland in 2007

Table S2 NIC and total expenditure for the individual STOPP criteria as a proportion of the overall NIC and total expenditure of PIP in 2007

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.


1. Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007;63:177–86. [PMC free article] [PubMed]
2. Lau DT, Kasper JD, Potter DEB, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74. [PubMed]
3. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–84. [PubMed]
4. O'Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37:138–41. [PubMed]
5. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, Lewis IK, Landsman PB, Cohen HJ. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47:891–6. [PubMed]
6. Fialova D, Onder G. Medication errors in elderly people: contributing factors and future perspectives. Br J Clin Pharmacol. 2009;67:641–5. [PMC free article] [PubMed]
7. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24. [PubMed]
8. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156:385–91. [PMC free article] [PubMed]
9. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7:103–7. [PubMed]
10. Aparasu RR, Mort JR. Inappropriate prescribing for the elderly: Beers criteria-based review. Ann Pharmacother. 2000;34:338–46. [PubMed]
11. Aparasu RR, Mort JR. Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. Am J Geriatr Pharmacother. 2004;2:102–11. [PubMed]
12. van der Hooft CS, Jong GW't, Dieleman JP, Verhamme KMC, van der Cammen TJM, Stricker BHC, Sturkenboom MCJM. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria – a population-based cohort study. Br J Clin Pharmacol. 2005;60:137–44. [PMC free article] [PubMed]
13. Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, Schroll M, Onder G, Sorbye LW, Wagner C, Reissigova J, Bernabei R. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293:1348–58. [PubMed]
14. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83. [PubMed]
15. Carey IM, De Wilde S, Harris T, Victor C, Richards N, Hilton SR, Cook DG. What factors predict potentially inappropriate primary care prescribing in older people? Drugs Aging. 2008;25:639–706. [PubMed]
16. De Wilde S, Carey IM, Harris T, Richards N, Victor C, Hilton SR, Cook DG. Trends in potentially inappropriate prescribing amongst older UK primary care patients. Pharmacoepidemiol Drug Saf. 2007;16:658–67. [PubMed]
17. Liu GG, Christensen DB. The continuing challenge of inappropriate prescribing in the elderly: an update of the evidence. J Am Pharm Assoc (Wash) 2002;42:847–57. [PubMed]
18. Naughton C, Bennett K, Feely J. Prevalence of chronic disease in the elderly based on a national pharmacy claims database. Age Ageing. 2006;35:633–6. [PubMed]
19. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2007.
20. Ryan C, O'Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. Ann Pharmacother. 2009;43:1239–44. [PubMed]
21. Gray J, Majeed A, Kerry S, Rowlands G. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ. 2000;321:548–50. [PMC free article] [PubMed]
22. Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med. 2004;164:305–12. [PubMed]
23. Aronson JK. In defence of polypharmacy. Br J Clin Pharmacol. 2004;57:119–20. [PMC free article] [PubMed]
24. Health Services Executive (HSE) Dublin, Ireland: Health Services Executive (HSE); 2007. Primary care reimbursement services: statistical analysis of claims and payments.
25. NICE. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. Technology appraisal guidance. 2000. p. 7.
26. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2–3. [PMC free article] [PubMed]
27. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445–8. [PubMed]
28. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53. [PubMed]
29. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9. [PMC free article] [PubMed]
30. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63:136–47. [PMC free article] [PubMed]
31. De Smet PAGM, Wilma D, Kramers C, Grol R. A composite screening tool for medication reviews of outpatients. Drugs Aging. 2007;24:733–60. [PubMed]
32. Tinetti ME. Preventing falls in elderly persons. N Engl J Med. 2003;348:42–9. [PubMed]
33. Krol N, Wensing M, Haaijer-Ruskamp F, Muris JWM, Numans ME, Schattenberg G, Van Balen J, Grol R. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther. 2004;19:917–22. [PubMed]
34. Messier S, Legault C, Mihalko S, Miller G, Loeser R, DeVita P, Lyles M, Eckstein F, Hunter DJ, Williamson JD, Nicklas BJ. The Intensive Diet and Exercise for Arthritis (IDEA) Trial: design and rationale. BMC Musculoskelet Disord. 2009;10:93. [PMC free article] [PubMed]
35. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329:324–9. [PMC free article] [PubMed]
36. Haumschild MJ, Karfonta TL, Haumschild MS, Phillips SE. Clinical and economic outcomes of a fall-focused pharmaceutical intervention program. Am J Health Syst Pharm. 2003;60:1029–32. [PubMed]
37. Gorgels WJMJ, Oude Voshaar RC, Mol AJJ, van de Lisdonk EH, van Balkom AJLM, van den Hoogen HJM, Mulder J, Breteler MHM, Zitman FG. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend. 2005;78:49–56. [PubMed]
38. Batty GM, Oborne CA, Swift CG, Jackson SHD. Development of an indicator to identify inappropriate use of benzodiazepines in elderly medical in-patients. Int J Geriatr Psychiatry. 2000;15:892–6. [PubMed]
39. Agostini JV. Measuring drug burden: a step forward. Arch Intern Med. 2007;167:753–4. [PubMed]
40. Higashi T, Shekelle PG, Solomon DH, Knight EL, Roth C, Chang JT, Kamberg CJ, MacLean CH, Young RT, Adams J, Reuben DB, Avorn J, Wenger NS. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med. 2004;140:714–20. [PubMed]
41. Kuijpers MAJ, van Marum RJ, Egberts ACG, Jansen PAF. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65:130–3. [PMC free article] [PubMed]
42. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing. 2008;37:673–9. [PubMed]
43. Fillenbaum GG, Hanlon JT, Landerman LR, Artz MB, O'Connor H, Dowd B, Gross CR, Boult C, Garrard J, Schmader KE. Impact of inappropriate drug use on health services utilization among representative older community-dwelling residents. Am J Geriatr Pharmacother. 2004;2:92–101. [PubMed]
44. Page RL, II, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother. 2006;4:297–305. [PubMed]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...